Novartis AG

Investors are acutely focused on the loss of exclusivity (LOE) of Merck & Co.’s mega-blockbuster Keytruda (pembrolizumab) in 2028, but head of global clinical development and chief medical officer

Like a number of big pharma players, Sanofi is investing heavily in expanding its production footprint in the US but chief financial officer François Roger has talked up the importance of Europe to th

The European Medicines Agency has started reviewing for potential pan-EU marketing authorization 15 new drugs, including Novo Nordisk’s semaglutide for the treatment of non-cirrhotic metabolic dysfunc

The heads of two of Europe’s pharma powerhouses have urged the EU to increase drug prices towards levels paid in the US, a move which is unlikely to be greeted with enthusiasm on the cash-strapped con